Herbert Virgin is the chief scientific officer and VP of research for infectious disease therapeutics company, Vir Biotechnology.
In his role at Vir, Virgin leads the company’s internal R&D programs, working to transform the care of patients with serious infectious diseases.
Prior to his time with Vir, Virgin served as a faculty member at the Washington University School of Medicine from 1990 to 2019, serving as the department chair of pathology and immunology and the Edward Millinckrodt professor from 2006 to 2017. His laboratory at the university used structural, genetic, sequencing and computational methods to identify mechanisms of immunity and viral pathogenesis in vivo. Virgin still serves as a non-tenured faculty member.
Virgin's early career was characterized by his internal medicine training at Boston’s Brigham and Women’s Hospital, as well as training in infection diseases at St. Louis’ Barnes Hospital. He is part of the National Academy of Sciences, the American Society for Clinical Investigation, the Association of American Physicians and the American Academy of Microbiology. Additionally, he serves on the editorial boards of Cell, Cell Host and Microbe.
Virgin holds a bachelor’s degree in biology, along with an M.D. and Ph.D. in immunology from Harvard University and Harvard Medical School.
What is Herbert Virgin's net worth?
The estimated net worth of Herbert Virgin is at least $834,753.00 as of September 7th, 2021. Dr. Virgin owns 103,825 shares of Vir Biotechnology stock worth more than $834,753 as of April 25th. This net worth evaluation does not reflect any other assets that Dr. Virgin may own. Learn More about Herbert Virgin's net worth.
How do I contact Herbert Virgin?
Has Herbert Virgin been buying or selling shares of Vir Biotechnology?
Herbert Virgin has not been actively trading shares of Vir Biotechnology during the last ninety days. Most recently, Herbert Virgin sold 1,375 shares of the business's stock in a transaction on Tuesday, February 22nd. The shares were sold at an average price of $30.00, for a transaction totalling $41,250.00. Learn More on Herbert Virgin's trading history.
Who are Vir Biotechnology's active insiders?
Vir Biotechnology's insider roster includes Ann Hanly (CTO), Howard Horn (CFO), Robert More (Director), Janet Napolitano (Director), Phillip Pang (Insider), Jay Parrish (Insider), Saira Ramasastry (Director), Steven Rice (Insider), Vicki Sato (Director), George Scangos (CEO), and Herbert Virgin (EVP). Learn More on Vir Biotechnology's active insiders.
Are insiders buying or selling shares of Vir Biotechnology?
In the last twelve months, insiders at the sold shares 26 times. They sold a total of 775,857 shares worth more than $17,733,362.17. The most recent insider tranaction occured on April, 3rd when CEO Backer Marianne De sold 72,995 shares worth more than $690,532.70. Insiders at Vir Biotechnology own 18.1% of the company.
Learn More about insider trades at Vir Biotechnology. Information on this page was last updated on 4/3/2024.
